Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
A federal appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb, brought by UMB Bank for former Celgene shareholders, after a lower court dismissal. The suit alleges Bristol Myers slowed FDA approvals for three drugs, including Breyanzi, tied to $9 per-share contingent value rights from its 2019 Celgene acquisition.
How this was made
The 30-second read
Why it matters
A federal appeals court reversed a dismissal on standing grounds, reinstating claims that Bristol Myers slowed FDA approvals to avoid a payout under the CVR terms.
Market read
Traders may reassess litigation tail-risk and potential settlement/damages expectations for BMY following the reinstatement of a large CVR-linked claim.
What to watch
The article notes a separate UMB lawsuit was allowed to proceed in December, but does not clarify how the revived case interacts with that docket or the ultimate damages framework.
Background
The suit traces to Bristol Myers’ 2019 $80.3B acquisition of Celgene, where CVR holders were owed $9 per share if timely FDA approvals were achieved for three drugs.
Ticker impact
Bristol Myers Squibb faces a 3-0 appeals court ruling reinstating a $6.7B lawsuit over alleged deliberate delays in FDA approvals for Breyanzi and two other drugs.
Near-term volatility risk, with downside skew if investors price higher settlement odds or broader CVR-related exposure.
The decision revives a large shareholder-linked claim tied to specific FDA approval timing and contract interpretation, but the article does not quantify damages or settlement probability.
Market effects
Highlights litigation risk for pharma acquirers tied to FDA timing covenants and contingent value rights structures.
Primarily US legal/regulatory process risk for large-cap pharma; limited direct cross-region impact implied.
US FDA approval timing disputes can influence global deal-risk perceptions for multinational pharma M&A structures.
Counterpoint
Even with reinstatement, Bristol Myers may still prevail on merits or limit damages; reinstatement does not equal liability.
Key entities
- companyBristol Myers Squibb
Defendant in the reinstated $6.7B lawsuit tied to alleged delays in FDA approvals for Breyanzi and two other Celgene drugs.
- financial_institutionUMB Bank
Plaintiff trustee acting on behalf of former Celgene shareholders under the CVR structure.
- companyCelgene
2019 acquisition target whose shareholders’ CVR economics are at the center of the dispute.
- court2nd U.S. Circuit Court of Appeals
Reinstated the lawsuit after finding the lower court wrongly dismissed it.
